FITC Mouse Anti-Human CD47 Antibody (S-3383)

CD47 is a widely expressed transmembrane glycoprotein recognized for transmitting a "don't eat me" signal upon binding to signal regulatory protein alpha (SIRPα) on macrophages, thereby inhibiting phagocytosis and protecting healthy cells—especially red blood cells—from clearance. Initially identified as integrin-associated protein (IAP), it also interacts with other ligands such as thrombospondin-1 and various integrins, playing a broad role in regulating cell proliferation, migration, apoptosis, and immune homeostasis. However, many tumor cells exploit this mechanism by upregulating CD47 to evade immune surveillance, positioning CD47 as a promising target for cancer immunotherapy. Although CD47-targeting agents such as Magrolimab have shown antitumor activity in clinical trials, the widespread expression of CD47 on normal cells, particularly erythrocytes, results in significant on-target, off-tumor hematologic toxicities (e.g., anemia)—a major challenge hindering clinical translation. Current research is therefore focused on developing tumor-specific bispecific antibodies or combination strategies to mitigate this risk.